贝尼地平对糖尿病大鼠肾脏保护作用的机制探讨

被引:1
作者
吴甘霖
贾汝汉
肖圣顺
丁国华
机构
[1] 武汉大学人民医院肾内科(武汉市第三人民医院肾内科)
[2] 武汉大学人民医院肾内科
关键词
糖尿病肾病; 贝尼地平;
D O I
暂无
中图分类号
R692 [肾疾病]; R587 [胰岛疾病];
学科分类号
100201 [内科学]; 100221 [泌尿外科学];
摘要
目的 观察贝尼地平对糖尿病大鼠肾小管上皮细胞间充质转分化的影响并探讨其机制。方法 54只180~200 g雄性Wistar大鼠采用随机数字表法分为正常对照组(8只)、糖尿病肾病造模组(46只),糖尿病肾病组空腹12 h后一次性腹腔内注射链脲佐菌素(60 mg/kg),对照组注射等量生理盐水。将37只造模成功的大鼠用随机数字表法分为3组,其中糖尿病组(13只),法舒地尔组(12只,10 mg·kg-1·d-1腹腔注射),贝尼地平组(12只,3 mg·kg-1·d-1灌胃)。治疗3个月后处死,HE染色观察肾脏病理变化,免疫组织化学观察肾脏皮质Rho激酶1(ROCK1)、α-平滑肌肌动蛋白(α-SMA)、上皮型-钙黏附蛋白(E-cadherin)的变化;Western Blot法观察肾皮质肌球蛋白磷酸酶目标亚单位1(p-MYPT1)、ROCK1、α-SMA、E-cadherin的变化;实时PCR观察ROCK1的mRNA变化。采用单因素方差分析及SNK或LSD检验进行统计学分析。结果 正常对照组、糖尿病组、贝尼地平组大鼠肾皮质内ROCK1蛋白表达分别为0.39(0.23~0.55)、0.93(0.64~1.28)、0.61(0.52~0.90),p-MYPT1、α-SMA蛋白表达糖尿病组增强、贝尼地平组减弱,差异有统计学意义(F值分别为7.37和125.26,均P<0.01),E-cadherin蛋白的表达分别为0.95±0.27,0.25±0.09,0.44±0.10,差异有统计学意义(F=28.15,P<0.05),ROCK1 mRNA的表达分别为4.4±2.2,23.3±7.0,15.9±3.4,差异有统计学意义(F=18.47,P<0.01)。结论 贝尼地平可能通过抑制ROCK活性减轻糖尿病鼠肾小管上皮细胞间充质转分化和肾间质纤维化。
引用
收藏
相关论文
共 12 条
[1]
Adiponectin stimulates phosphorylation of AMP-activated protein kinase α in renal glomeruli [J].
Cammisotto, Philippe G. ;
Bendayan, Moise .
JOURNAL OF MOLECULAR HISTOLOGY, 2008, 39 (06) :579-584
[2]
Elevated levels of high-molecular-weight adiponectin in type 1 diabetes [J].
Leth, Henrik ;
Andersen, Kristian K. ;
Frystyk, Jan ;
Tarnow, Lise ;
Rossing, Peter ;
Parving, Hans-Henrik ;
Flyvbjerg, Allan .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2008, 93 (08) :3186-3191
[3]
Blockade of T-type voltage-dependent Ca 2+ channels by benidipine; a dihydropyridine calcium channel blocker; inhibits aldosterone production in human adrenocortical cell line NCI-H295R.[J].Osamu Akizuki;Atsushi Inayoshi;Tetsuya Kitayama;Kozo Yao;Shiro Shirakura;Katsutoshi Sasaki;Hideaki Kusaka;Masahiro Matsubara.European Journal of Pharmacology.2008, 2
[4]
Adiponectin regulates albuminuria and podocyte function in mice [J].
Sharma, Kumar ;
RamachandraRao, Satish ;
Qiu, Gang ;
Usui, Hitomi Kataoka ;
Zhu, Yanqing ;
Dunn, Stephen R. ;
Ouedraogo, Raogo ;
Hough, Kelly ;
McCue, Peter ;
Chan, Lawrence ;
Falkner, Bonita ;
Goldstein, Barry J. .
JOURNAL OF CLINICAL INVESTIGATION, 2008, 118 (05) :1645-1656
[5]
Targeting of RhoA/ROCK signaling ameliorates progression of diabetic nephropathy independent of glucose control [J].
Kolavennu, Vasantha ;
Zeng, Lixia ;
Peng, Hui ;
Wang, Yin ;
Danesh, Farhad R. .
DIABETES, 2008, 57 (03) :714-723
[6]
Rho kinase inhibition: A new approach for treating diabetic nephropathy? [J].
Bach, Leon A. .
DIABETES, 2008, 57 (03) :532-533
[7]
Changes in adiponectin receptor expression in muscle and adipose tissue of type 2 diabetic patients during rosiglitazone therapy [J].
Tan, GD ;
Debard, C ;
Funahashi, T ;
Humphreys, SM ;
Matsuzawa, Y ;
Frayn, KN ;
Karpe, F ;
Vidal, H .
DIABETOLOGIA, 2005, 48 (08) :1585-1589
[8]
Differential blocking action of dihydropyridine Ca2+ antagonists on a T-type Ca2+ channel (α1G) expressed in Xenopus oocytes [J].
Furukawa, T ;
Nukada, T ;
Miura, R ;
Ooga, K ;
Honda, M ;
Watanabe, S ;
Koganesawa, S ;
Isshiki, T .
JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 2005, 45 (03) :241-246
[9]
Effects of benidipine; a dihydropyridine-Ca 2+ channel blocker; on expression of cytokine-induced adhesion molecules and chemoattractants in human aortic endothelial cells.[J].Masahiro Matsubara;Kazuhide Hasegawa.European Journal of Pharmacology.2004, 1
[10]
Urinary adiponectin excretion is increased in patients with overt diabetic nephropathy [J].
Koshimura, J ;
Fujita, H ;
Narita, T ;
Shimotomai, T ;
Hosoba, M ;
Yoshioka, N ;
Kakei, M ;
Fujishima, H ;
Ito, S .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2004, 316 (01) :165-169